More recently, SGLT2 (sodium-glucose transporter 2) inhibitors were shown to promote a decrease in blood glucose due to increased excretion through the kidneys, although there have been indications of increased risk of diabetic ketoacidosis and urinary tract infections1,31. This evidence concerns the gene SLC5A2 and diabetic ketoacidosis.